IJPH - Year 8, Volume 7, Number 3, Suppl. 2, 2010 I T A L I A N J O U R N A L O F P U B L I C H E A L T H minor numero di viaggi) [22]. Alla luce della considerazioni sopra esplic<strong>it</strong>ate, appare opportuno estendere l’impiego del nuovo regime all’interno del terr<strong>it</strong>orio nazionale in quanto esso, oltre a presentare risultati clinici di prim’ordine, comporta notevoli vantaggi <strong>economici</strong> associati prevalentemente alla possibil<strong>it</strong>à di gestione domiciliare della nuova terapia da parte dei pazienti. Bibliografia 1) Giuliani G, Lucioni C, Mazzi S, De Carli C, Jamieson C. Valutazione di convenienza economica comparata tra un farmaco orale (capec<strong>it</strong>abina) e una terapia parenterale a base di 5-FU (regime Mayo) nel trattamento del tumore del colon-retto metastatizzato. Pharmacoeconomics, Italian Research Articles 2002;4 (1):13-38. 2) La Torre G, Chiaradia G, de Waure C, Nicolotti N, Monteduro A, Ricciardi W. Report HTA del vaccino quadrivalente anti-HPV Gardasil. Ital J Public Health 2009;6(suppl 2). 3) Belovich D, Hux M, Douglas P, Maroun JA, Sommer N. Cost-effectiveness of capec<strong>it</strong>abine in combination w<strong>it</strong>h oxaliplatin (XELOX) compared w<strong>it</strong>h FOLFOX for the treatment of metastatic colorectal cancer: A Canadian evaluation. J Clin Oncol 2009;27 (suppl; abstract e17502). 4) Garrison L, Guiliani G, Ducournau P, et al. Cost analysis of XELOX vs. FOLFOX-4 ± Avastin (bev) in metastatic colorectal cancer (MCRC) from an Italian hosp<strong>it</strong>al perspective. ISPOR Europe 2007b, 20–23 October, Dublin, Ireland, Abstr PCN38. 5) Garrison L, Cassidy J, Saleh M, et al. Cost comparison of XELOX compared to FOLFOX4 w<strong>it</strong>h or w<strong>it</strong>hout Avastin (bev) in metastatic colorectal cancer. J Clin Oncol 2007a ASCO Annual Meeting Proceedings Part I; 25(18S) June 20 Suppl:4074. 6) Perrocheau G, Bennouna J, Ducreaux M, et al. Costminimization analysis of a phase III study of capec<strong>it</strong>abine + oxaliplatin (XELOX) vs infusional 5-FU/LV + oxaliplatino (FOLFOX-6) as first-line treatment for metastatic colorectal cancer (MCRC) in the French setting. J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I; 25(18S) June 20 Suppl:4083. 7) Jansman FGA, Postma MJ, van Hartskamp D, Willemse PHB, Brouwers JRBJ. Cost-benef<strong>it</strong> analysis of capec<strong>it</strong>abine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands. ClinTher 2004;26(4):579-89. 8) Cassidy J, Douillard J-Y, Twelves C, et al. Pharmacoeconomic analysis of adjuvant capec<strong>it</strong>abine vs intravenous 5 FU/LV in Dukes’ C colon cancer: X-ACT trial. BJC 2006;94:1122-29. 9) Conroy T, Hebbar M, Bennouna J, et al. Qual<strong>it</strong>y-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer. BJC 2010;102:59-67. 10) Manidakis N, Fragoulakis V, Pectasides D, Fountzilas G. XELOX vs FOLFOX 6 as an adjuvant treatment in colorectal cancer: an economic analysis. Curr Med Res and Op 2009;25(3):797-805. 11) Brandi G, Di Cicilia R, Di Battista M, et al. Capec<strong>it</strong>abine (CAP) based regimens vs infusional 5-FU/FA in metastatic colorectal cancer cost/effectiveness: the differences across the atlantic Ocean. Ann Oncol 2008; 19 (suppl 9). Disponibile online al s<strong>it</strong>o: http://annonc.oxfordjournals.org/content/19/ suppl_9/ix63.full.pdf+html (Ultimo accesso: 15.06.2010). 12) Antonuzzo L, Negrini C, Gasperoni S, et al. Pharmacoeconomic analysis of adjuvant chemotherapy w<strong>it</strong>h fluoropymidine in colon cancer. Ann Oncol 2008; 19 (suppl 9). Disponibile online al s<strong>it</strong>o: http://annonc.oxfordjournals. org/content/19/suppl_9/ix63.full.pdf+html (Ultimo accesso: 15.06.2010). 13) Chu E, Cartwright T H. Pharmacoeconomic benef<strong>it</strong>s of capec<strong>it</strong>abine-based chemotherapy in metastatic colorectal cancer. J Clin Oncol 2008; 26(13): 2224-6. 14) Shiroiwa T, Furkuda T, Tzutani K. Health util<strong>it</strong>y scores of colorectal cancer based on societal preference in Japan. Qual Life Res 2009;18:1095–103. 15) Lopatriello S, Amoroso D, Donati S, et al The CAP-CR study: direct medical costs in Italian metastatic colorectal cancer patients on first line infusional 5-Fluorouracil or oral capec<strong>it</strong>abine. EJC 2008, 44: 2615-22. 16) Araújo DV, Cirrincione A. Cost of colorectal cancer treatment in elderly patients. BJGG 2006;9(1): 72-81. 17) Lopatriello S, Negrini C, Amoroso D, Donati S. Gestione del paziente affetto da tumore del colon-retto metastatico: conseguenze economiche dei diversi percorsi terapeutici. Farmacoeconomia e percorsi terapeutici 2009;10(3): 141-6. 18) Shiroiwa T, Furkuda T, Tzutani K. Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO 16996 and NO 16967 trials. BJC 2009;101:12-8. 19) Shiroiwa T, Fukuda T, Tsutani K. Cost-effectiveness analysis of bevacizumab combined w<strong>it</strong>h chemotherapy for the treatment of metastatic colorectal cancer in Japan. Clin Ther 2007;29(10): 2256-67. 20) Saltz L B, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination w<strong>it</strong>h oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a ranzomized phase III study. J Clin Oncol 2008;26: 2013-19. 21) Rothenberg M L, Cox J V, Butts C, et al. Capec<strong>it</strong>abine plus oxaliplatin (XELOX) vs 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second line therapy in metastatic colorectal cancer: a randomized phase III noninferior<strong>it</strong>y study. Ann Oncol 2008;19:1720-6. 22) Di Costanzo F, Antonuzzo L, Rotella V, Negrini C. Analisi farmacoeconomica in pazienti trattati con capec<strong>it</strong>abina in terapia adiuvante. Clin Prac 2008; 10:17-25. 23) Goerner M, Riemer-Hommel P. Economic impact of Alternative Adjuvant Chemoterapy Regimens for Stage III Colon Cancer. Onkologie 2009; 32:647-52. C A P I T O L O 5 S 6 9
IJPH - Year 8, Volume 7, Number 3, Suppl. 2, 2010 I T A L I A N J O U R N A L O F P U B L I C H E A L T H 24) Sche<strong>it</strong>hauer W, Cassidy J, Figer A, et al. A comparison of medical resource use for 4 chemotherapy regimens as first-line treatment for metastatic colorectal cancer (MCRC): XELOX vs FOLFOX4 ± Avastin (A). J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I;25(18S) June 20 Suppl:40980. 25) Schmoll HS, Cartwright T, Tabernero J, et al. Phase III Trial of Capec<strong>it</strong>abine Plus Oxaliplatin As Adjuvant Therapy for Stage III Colon Cancer: A Planned Safety Analysis in 1,864 Patients. J Clin Oncol 2007;1(25): 102-9. S 7 0 C A P I T O L O 5
- Page 1 and 2: IJPH - Year 8, Volume 7, Number 3,
- Page 3 and 4: IJPH - Year 8, Volume 7, Number 3,
- Page 5 and 6: IJPH - Year 8, Volume 7, Number 3,
- Page 7 and 8: IJPH - Year 8, Volume 7, Number 3,
- Page 9 and 10: IJPH - Year 8, Volume 7, Number 3,
- Page 11: IJPH - Year 8, Volume 7, Number 3,
Change language